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Abstract

Using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), previous study showed
significant gender differences for cognitive deficits in immediate and delayed memory in schizophrenia
patients. However, RBANS does not include reasoning and problem solving, and social cognition. These
cognitive functions can significantly affect the outcomes and daily life in patients. This study examined the
gender differences of cognition using the measurement and treatment research to improve cognition in
schizophrenia (MATRICS) consensus cognitive battery (MCCB), especially focusing on reasoning and
problem solving, and social cognition in schizophrenia patients. The results showed that healthy controls
exemplified better cognition than patients in both genders in all examined MCCB scores. Male healthy
controls had better reasoning and problem solving and working memory than females, but these gender
differences were not presented in schizophrenia patients. Also, male schizophrenia patients showed worse
cognition than females on social cognition, processing speed, verbal learning and visual learning. Our results
support that male schizophrenia patients had more cognitive impairment than females on reasoning and
problem solving, social cognition, processing speed, working memory, verbal learning and visual learning.
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Gender differences measured by
the MATRICS consensus cognitive
battery in chronic schizophrenia
patients
Baohua Zhang1,2, Mei Han2, Shuping Tan1, Fu De Yang1, Yunlong Tan1, Shurong Jiang1,
Xiangyang Zhang1,3 & Xu-Feng Huang 2
Using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), previous study
showed significant gender differences for cognitive deficits in immediate and delayed memory in
schizophrenia patients. However, RBANS does not include reasoning and problem solving, and social
cognition. These cognitive functions can significantly affect the outcomes and daily life in patients. This
study examined the gender differences of cognition using the measurement and treatment research to
improve cognition in schizophrenia (MATRICS) consensus cognitive battery (MCCB), especially focusing
on reasoning and problem solving, and social cognition in schizophrenia patients. The results showed
that healthy controls exemplified better cognition than patients in both genders in all examined
MCCB scores. Male healthy controls had better reasoning and problem solving and working memory
than females, but these gender differences were not presented in schizophrenia patients. Also, male
schizophrenia patients showed worse cognition than females on social cognition, processing speed,
verbal learning and visual learning. Our results support that male schizophrenia patients had more
cognitive impairment than females on reasoning and problem solving, social cognition, processing
speed, working memory, verbal learning and visual learning.
Cognitive deficit is one of the core features of schizophrenia1. Cognitive deficit directly affect the quality of life
and employment in schizophrenia patients2. Gender differences are recognized in brain neurotransmitter and
receptors and function as well as their influence in behavior including in schizophrenia patients. Schizophrenia
patients show gender differences in clinical symptoms, course and treatment outcome3. Several studies have
reported gender differences in relation to cognitive deficits in schizophrenia4–6. An in-depth investigation of gender difference of cognitive deficits could help us to guide preclinical and clinical research and possible new ideas
for a better treatment for patients.
Although we and others have used the repeatable battery for the assessment of neuropsychological status
(RBANS) to report that the immediate memory and delayed memory were poorer in male than female chronic
schizophrenia patients7–9. RBANS was initially introduced to provide neuropsychological assessment in screening for dementia10. It has since been shown to be valid for other mental illnesses including schizophrenia11. The
major weakness of RBANS is that its cognitive measurement does not include reasoning and problem solving,
and social cognition. These cognitive domains can significantly affect quality of life and independent living skills
in schizophrenia, including relapse, worsened symptoms, and resulting unemployment12–15. The gender differences of cognitive impairment on reasoning and problem solving, or social cognition have not been systemically
investigated in schizophrenia patients. In addition, some studies failed to find any gender differences of cognitive
deficits in schizophrenia patients, or found better cognition in male schizophrenia patients than females16,17.
Therefore, the gender differences of cognitive function in schizophrenia patients remained controversial and
deserve further investigation.
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Variables

Schizophrenia Patients
(n = 192)

Healthy Controls
(n = 160)

F or χ2

P-value

Gender (male/female)

112/80

80/80

2.44

> 0.05

Age (years)

47.3 ± 7.9

44.7 ± 11.0

3.59

> 0.05

Education (years)

10.8 ± 2.1

10.0 ± 3.6

3.81

> 0.05

Table 1. Demographic characteristics in schizophrenia patients and healthy controls Mean ± SD (standard
deviation).

Age (years)

Male

Female

F or χ2

p-value

47.6 ± 8.5

47.6 ± 7.1

0.48

0.49
0.06

Education (years)

10.6 ± 2.1

11.2 ± 2.1

3.73

Age at onset of illness

22.5 ± 5.4

25.7 ± 7.3

11.13

< 0.01

Duration of illness

24.9 ± 9.3

21.3 ± 10.2

5.75

< 0.05

Antipsychotic type (typicals/atypicals)

13/99

9/71

0.00

0.83

Antipsychotic dose (CPZ equivalents)(mg)

365.9 ± 312.8

392.1 ± 218.9

0.35

0.56

Score on positive symptom scale

12.0 ± 4.5

13.5 ± 5.7

3.66

0.06

Score on negative symptom scale

17.9 ± 5.2

17.8 ± 5.8

0.03

0.87

Score on general psychopathology scale

27.4 ± 5.4

28.1 ± 6.2

0.63

0.43

Total PANSS score

61.1 ± 11.2

63.0 ± 14.4

0.94

0.33

Table 2. Characteristics of patients with schizophrenia grouped by gender Note: Mean ± SD.
CPZ = chlorpromazine; PANSS = the positive and negative syndrome scale.

Measurement and treatment research to improve cognition in schizophrenia (MATRICS) was originally
developed by the US National Institute of Mental Health (NIMH). The primary goal of the NIMH-MATRICS was
to encourage the development of pharmacological agents to improve cognition in schizophrenia18. The MATRICS
consensus cognitive battery (MCCB) was widely developed to measure cognitive function in schizophrenia
patients after the cognitive measure method has been evaluated based on its test-retest reliability, high utility as a
repeated measure, relationship to functional outcome, practicality and tolerability, which was accepted by most
medical researchers18. Importantly, the MCCB cognitive measure includes reasoning and problem solving and
social cognition, which were important domains of cognitive deficits in schizophrenia. In recent years, MCCB for
cognitive measurement has been translated into Chinese, and its clinical validity and test-retest reliability have
been established between schizophrenia patients and health controls19. The MCCB has been applied in cognition
studies for schizophrenia patients in Chinese population20,21.
To the best of our knowledge, no previous study has investigated the gender differences of cognitive deficits
in schizophrenia patients in the Chinese Han population using MCCB. The purpose of this study was to verify:
(1) whether or not schizophrenia patients had gender differences in cognitive deficits for reasoning and problem
solving, and social cognition; (2) if the gender differences identified in our previous study9 using RBANS can be
confirm using MCCB; and (3) whether the gender differences of cognitive deficits in schizophrenia were associated with specific clinical characteristics and symptoms.

Results

Demographic and clinical data in schizophrenia patients and healthy controls.

Table 1 showed
no significant difference between schizophrenia patients and healthy controls in age, gender and education. There
were significant gender differences in the age at onset of illness and duration of illness (p < 0.001 or p < 0.05)
in schizophrenia patients (Table 2). In addition, there were no significant differences between male and female
schizophrenia patients in any of the PANSS scores, the ratio of typical to atypical antipsychotics, and the antipsychotic dose (equivalent to chlorpromazine) (Table 2).

Cognitive performance in schizophrenia patients and healthy controls. After controlling for
age and education, multivariate analysis of covariance revealed significant differences in all cognitive domains
between schizophrenia patients and healthy controls (F1,191 = 28.6, p < 0.001). Furthermore, diagnosis (schizophrenia patients vs healthy subjects) was significantly different for the MCCB total and all subtest scores (all
p < 0.001). Male schizophrenia patients had significantly lower cognitive MCCB total and subtest scores (all
p < 0.001) than male healthy subjects, with effect sizes ranging from 0.79 to 2.09. Female patients also had significantly lower cognitive MCCB total and subtest scores (all p < 0.001 or p < 0.01) than female healthy subjects,
with effect sizes ranging from 0.42 to 1.35.
Multivariate analysis of covariance also revealed overall main effects for gender on symbol coding of processing speed, reasoning and problem solving (both p < 0.001). Also, analysis showed significant gender x diagnosis
interaction effects on working memory, verbal learning and visual learning (p < 0.01 or p < 0.05). To further
analyze these two-way interactions, we compared cognitive function in schizophrenia patients or healthy controls
separately by gender. Male schizophrenia patients performed poorer than females on symbol coding of processing
speed, verbal learning, visual learning, and social cognition (p < 0.001or p < 0.05), with effect sizes ranging from
Scientific Reports | 7: 11821 | DOI:10.1038/s41598-017-12027-w
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Figure 1. The cognitive test scores by MCCB in schizophrenia patients and healthy controls. Subtest-1: Symbol
coding of processing speed; Subtest-2: Digital sequence of working memory; Subtest-3: Spatial span total of
working memory; Subtest-4: Verbal learning; Subtest-5: Visual learning; Subtest-6: Reasoning and problem
solving; Subtest-7: Social cognition. ***p < 0.001, **p < 0.01 and *p < 0.05. SZ: Schizophrenia patients;
HC: Healthy controls. MCCB: MATRICS (Measurement and Treatment Research to Improve Cognition in
Schizophrenia) Cognitive Consensus Batterys.

0.44 to 0.69 (Fig. 1). Furthermore, the gender differences assessment on symbol coding of processing speed and
visual learning passed Bonferroni corrections (all p < 0.01) but verbal learning and social cognition did not pass
Bonferroni corrections (all p > 0.05). Male healthy controls had better cognitive performance than females in
working memory (including digital sequence and spatial span total), reasoning and problem solving (p < 0.01
or p < 0.05), with effect sizes ranging from 0.39 to 0.42 (Fig. 1). Also, reasoning and problem solving and digital
sequence of working memory passed Bonferroni corrections (all p < 0.05) but the spatial span total for working
memory did not pass the Bonferroni corrections (p > 0.05) in healthy subjects.

Relationship between cognitive performance and clinical variables in schizophrenia
patients. Multivariate regression analysis showed that MCCB total score was independently associated with

PANSS negative symptom score (beta = −0.497, t = −4.016, p < 0.001) and gender (beta = 3.237, t = 2.325,
p < 0.05). These factors together predicted 12% of the variance of the total MCCB score.
The symbol coding score of processing speed was independently associated with age (beta = −0.556,
t = −6.044, p < 0.001), gender (beta = 6.088, t = 4.346, p < 0.001), education (beta = 1.029, t = 2.974, p < 0.01),
and PANSS negative symptom score (beta = −0.323, t = −2.631, p < 0.01). These factors together predicted 37%
of the variance of the symbol coding score.
Verbal learning was independently associated with age (beta = −0.556, t = −6.044, p < 0.001) and gender
(beta = 6.088, t = 4.346, p < 0.001). These factors together predicted 18% of the variance in verbal learning.
Visual learning was independently associated with the following variables: duration of illness (beta = −0.294,
t = −5.744, p < 0.001), gender (beta = 2.844, t = 2.757, p < 0.01), and PANSS negative symptom score
(beta = −0.220, t = −2.420, p < 0.05). These factors together predicted 25% of the variance in visual learning.
Social cognition was independently associated with education (beta = 0.191, t = 3.325, p < 0.01), and PANSS
negative symptom score (beta = −0.053, t = −2.396, p < 0.001). These factors together predicted 9% of the variance in social cognition.

Discussion

Compared to our previous study using RBANS cognitive measurement9, this study found more cognitive impairments on reasoning and problem solving, social cognition, processing speed and working memory in male than
female schizophrenia patients. This study also extended our previous study of cognitive deficits in both male
and female schizophrenia patients. Moreover, we found that male schizophrenia patients showed more severe
cognitive deficits than female patients in verbal learning and visual learning that was consistent with our previous using RBANS study9. Furthermore, schizophrenia patients showed greater cognitive deficits in all examined
cognitive domains than healthy controls for both genders, which were also consistent with our previous study
using RBANS9.
A direct comparison of reasoning and problem solving between male and female patients showed no difference, which differed from normal subjects that males perform better in reasoning and problem solving than
females. Therefore, our study suggest that male schizophrenia patients may have more cognitive impairment than
females on reasoning and problem solving, which is consistent with previous finding22. Male healthy controls
exemplified better reasoning and problem solving than females, which is also consistent with previous studies that
showed cognitive advantages in males than females on spatial reasoning tasks23.
Furthermore, our study suggested that social cognitive deficits were worse in male than female schizophrenia
patients, which was similar to previous observations24. Our results were in a line with some previous rodent studies mimicking schizophrenia-like behavior. For example, a reduction in social interaction was observed in male,
but not in female rats following neonatal treatment with domoic acid25. Folate-deficient mice showed reduced
social interaction in males but not females26. However, the pathophysiological mechanisms underlying the gender
differences in the social cognition for schizophrenia patients were not clear. Rodent study showed that serotonin
Scientific Reports | 7: 11821 | DOI:10.1038/s41598-017-12027-w
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MCCB

RBANS

Processing speed

Immediate memory

Category fluency

List learning d

Symbol coding

Story memory

a

Trail Making A

Visuospatial/constructional

Attention/Vigilance

Figure copy c

CPT-IP

Line orientation

Working memory

Language

Digital sequence b

Picture naming

Spatial span total c

Semantic fluency tasks

Verbal learning

Attention

HVLT-R total d

Digit span b

Visual learning

Coding Tasks a

BVMT-R total

Delayed memory

e

Reasoning and problem
solving

List recall

Mazes (NAB) total

List recognition

Social cognition

Story recall

MSCEIT

Figure recall e

Table 3. The lists of cognitive domains in MCCB and RBANS MCCB: Measurement and Treatment Research
to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery; CPT-IP: Continuous
Performance Test-Identical Pairs; HVLT: Hopkins Verbal Learning Test; BVMT: Brief Visuospatial Memory
Test; NAB: Neuropsychological Assessment Battery; MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence
Test. RBANS: Repeatable Battery for the Assessment of Neuropsychological Status. a–eSymbols indicate the
positive findings in MCCB, which they have the similar cognitive measure parameters with RBANS.

5-HT2A receptor expression was reduced in the prefrontal cortex, hypothalamus, and midbrain of social isolated
male mice27. Human study showed that 5-HT2A receptor −1438 A/G polymorphism in the promoter region may
influence social cognitive function in patients with schizophrenia28. These results suggested that 5-HT2A receptor or their genetic variants may be contributed to the gender differences of social cognition in schizophrenia
patients.
Processing speed is an important behavioural marker of the pathophysiology of schizophrenia29. This study
found that male schizophrenia patients had worse symbol coding processing speed than females, which was
consistent with previous studies30,31. Also, this study showed that gender was independently associated with the
symbol coding processing speed in schizophrenia patients. In addition, the rat model also supported that males
had worse processing speed that females32. These results suggested that gender difference exists in the processing
speed in schizophrenia patients. The symbol coding processing speed in MCCB is similar with coding tasks of
attention in RBANS (Table 3). However, our previous study did not find gender difference in attention for schizophrenia patients using RBANS9. The cognitive domains on attention did not distinguish subgroups (digit span
and coding tasks) using our previous RBANS study, which may be the possible reason for the negative discovery
of gender difference on attention9 (Table 3). Therefore, this distinction of subgroups using RBANS in cognitive
analysis may be important in future studies.
A direct comparison of working memory between male and female patients showed no difference, which differed from normal subjects that that males perform better in working memory than females. Therefore, our study
suggested that male schizophrenia patients may have more cognitive impairment than females, which is similar
finding as previous report33. The rodent study also showed some less impairments in female than male in working
memory34,35. The digital sequence of working memory in MCCB is equivalent to the digit span of attention in
RBANS (Table 3). The spatial span total of working memory in MCCB has considerable overlap with the figure
copy of visuospatial/constructional in RBANS (Table 3). Further, our previous study by Han et al. only addressed
cognitive analysis by immediate memory, visuospatial/constructional, language and delayed memory and did
not distinguish subgroups of these cognitive domains in RBANS9 (The details for subgroups of RBANS please see
the Table 3). This could have led to some negative findings in gender differences of cognition on attention and
visuospatial/constructional domains. In addition, other clinical study had opposite findings on gender difference
in working memory impairment in schizophrenia patients which was that female schizophrenia patients had
worse working memory than male patients36. Currently, we do not have a clearly explanation for the inconsistent
findings. It could be due to inconsistent and complex factors tested that may result in heterogeneity in the schizophrenia diagnosis, the course of the disease, antipsychotic treatments, and ethnic background. Prefrontal cortex
plays an important role in working memory37, which could warrant an imaging study to compare prefrontal
cortical differences between male and female schizophrenia patients.
The impairments of verbal and visual learning were found in schizophrenia patients compared to healthy
controls. Also, male schizophrenia patients had worse cognitive deficits than female patients on verbal and visual
learning domains. Post-hoc comparisons of schizophrenia patients and healthy controls yield significant interactions between gender and diagnosis (schizophrenia patients vs. healthy controls). Verbal and visual learning were
independently associated with gender in schizophrenia patients. These results supported that male schizophrenia
Scientific Reports | 7: 11821 | DOI:10.1038/s41598-017-12027-w
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patients had worse cognitive impairment than female patients on verbal and visual learning, which were consistent with other studies36,38. Verbal learning is related to immediate memory in RBANS (Table 3). Visual learning
is related to figure recall of delayed memory in RBANS (Table 3). Therefore, male schizophrenia patients had significantly worse cognitive deficits than females on verbal and visual learning in the study, which were consistent
with our previous RBANS results that male schizophrenia patients had worse immediate and delayed memory
impairment than females9.
Compared to healthy controls, this study found significant cognitive deficits in all seven examined cognitive
domains of MCCB in schizophrenia patients, which is consistent with ours and other previous studies9,39–41.
Interestingly, our previous study observed a cognitive impairment trend in visuospatial/constructional domain
in schizophrenia patients than healthy controls (p = 0.059)9. As described above, visuospatial/constructional
domain mainly composed of figure copy and line orientation tasks in RBANS (Table 3). The figure copy of visuospatial/constructional is mainly overlapping with spatial span total of working memory The line orientation task
of visuospatial/constructional is also mainly overlapping with trail making A for speed of processing in MCCB.
However, in this study, the trail making A for speed of processing and spatial span total of working memory
were found to incur significant impairment in schizophrenia patients compared to healthy controls. These results
prompted that it is important to analyse the visuospatial/constructional cognitive domain by subgroup (figure
copy and line orientation tasks) in using RBANS.
The effect of worse cognition for male schizophrenia patients compared to females in several cognitive
domains has been consistently identified by both our MCCB and RBANS studies. However, the pathophysiological mechanism of gender difference of cognitive deficits in schizophrenia is not clear. Currently, neuroprotective effects of sex hormones (especially estrogens) are among the most studied and accepted explanation
for gender difference in cognition9,14,42,43. Moreover, gender differences in response to antipsychotics treatment
could also contribute to the differential cognitive impairments in schizophrenia patients9,44–46, while some studies did not support such claim47–49. In addition, some studies suggested that an earlier onset of schizophrenia
was associated with the seriousness of the disease, including cognitive deficits50. Therefore, it should be noted
that male schizophrenia patients generally had an earlier age of onset for the illness and longer duration of
illness than female patients in this study, which might be one of reason that male schizophrenia patients performed worse cognitive deficits than females. However, other studies have failed to find differences in the cognitive profiles of individuals with early or late-onset schizophrenia51,52. Also, the excitation/inhibition imbalance
theory of biological psychiatry may explain the relative preferential effect of schizophrenic neuropathology on
particular mental processes53. This theory supports that gender differences in different cognitive domain may
have specific pathophysiology in schizophrenia patients. Also, a study suggested that gender specific differences in neurotransmitter levels in the medial prefrontal cortex and hippocampus may contribute to the gender
differences of cognitive deficits in schizophrenia patients54. Nevertheless, the pathophysiological mechanism
that resulted in better performance of cognition for females than males in schizophrenia patients still needs to
further be investigated.
In addition, our regression analysis revealed significant correlation between the symbol coding of processing
speed score and PANSS negative symptom score, visual learning and duration of illness. These results supported
that cognitive deficits was significantly related to the severity of negative symptoms and duration of illness of
schizophrenia.
This study has some limitations. Since this research is a phenomenological study, it does not explain the
molecular mechanisms of the gender differences or the pathophysiology of cognition in schizophrenia. First,
the schizophrenia patients in this study were of the chronic patients. Although there were no gender differences
in antipsychotic dose (CPZ equivalents) and antipsychotic type (typical/atypical), the duration of illness in male
patients were longer than female patients. We could not exclude that the gender effects of cognition in schizophrenia patients might be caused by disease duration and chronic drug treatment. Second, the cross-sectional
study provided a snapshot of the entire course of the disease. A future longitudinal study might help to reveal
the effects of disease progression. Third, the patients were all inpatients and therefore these results might not be
generalizable to all schizophrenia patients. Fourth, it should be mentioned that our results for spatial span of
working memory, verbal learning and social cognition did not pass the Bonferroni corrections test. Therefore,
these results should be carefully regarded. Furthermore, repeat analysis and larger sample size study might be
conducted. Fifth, mental status, personal and family history of mental illness for healthy controls were assessed
using unstructured interviews and were not assessed using structured interviews such as SCID. Therefore,
we cannot completely exclude the healthy controls from the potential of being subject to weak psychiatric
disorders.
In summary, compared to our previous using RBANS study, we have added new findings that male schizophrenia patients had worse cognitive impairment than females in symbol coding processing speed, working
memory, reasoning and problem solving, and social cognition measured by MCCB. We also found significant
gender differences in cognitive deficits in verbal and visual learning in schizophrenia patients, which were consistent with our previous study measured by RBANS. MCCB covers an equivalent range of cognitive measurements to RBANS and has additional advantaging in detecting deficits in reasoning, problem solving and social
cognition in schizophrenia patients.

Materials and Methods
Ethics statement.

A complete description of the study was given to all participants. All participants were
provided with written informed consent. A psychiatrist evaluated all the participants to test whether they had
the capacity to consent. The research procedure was explained during a detailed interview and the participants
acknowledged they understood what they were required to do. Language appropriate to the participant’s level of
comprehension and emotional readiness was used to maximise the understanding of the participants. If he/she
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was willing to participate in the research but was unable to understand the complexity of the research processes,
the research was simultaneously described to the parent or guardian and the patient. The parent or guardian then
explained the research process to the participants using those methods that gauged the participant’s interest and
maximised their understanding. In these situations, written consent was provided by the parent or guardian on
behalf of the participant. If the participant did not agree to participate in the research study, they were not discriminated against and were given the same treatment as the study participants.

Consent from study population. Informed consent has been obtained from the patients or their parents
and guardians to use the results for analysis and use information for online open-access publication before subjects were recruited. The study protocol was approved by the Institutional Review Board, Beijing HuiLongGuan
Hospital, and all methods were performed in accordance with the relevant guidelines and regulations.
Participants. One hundred and ninety two schizophrenia patients (male/female = 112/80) were recruited
using a cross-sectional naturalistic design at Beijing HuiLongGuan Hospital, a Beijing City owned psychiatric
hospital. The diagnoses for each patient were made by two independent and experienced psychiatrists and confirmed by the Chinese version of Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Research Version,
Patient Edition (SCID-I/P)55. All patients were aged between 20 and 60 years, diagnosed with schizophrenia for
at least 5 years, and were on stable doses of oral antipsychotic drugs for at least 12 months (ranging from 1 to 13
years) prior to entry into the study. Antipsychotic drugs consisted of monotherapy with atypical antipsychotics
including clozapine 50–600 mg/day (n = 86), risperidone 2–10 mg/day (n = 52), quetiapine 300–1000 mg/day
(n = 13), olanzapine 5–20 mg/day (n = 5), aripiprazole 10 mg/day (n = 1), and typical antipsychotics including
haloperidol 12–50 mg/day (n = 5), chlorpromazine 200 mg/day (n = 1), perphenazine 14–30 mg/day (n = 7),
sulpiride 100–1000 mg/day (n = 6), and others (n = 16). The mean antipsychotic dose (as chlorpromazine equivalents) was 379.2 ± 277.6 mg/day. Since admission, all patients received dietetically balanced hospital meals, which
were occasionally supplemented by gifts (usually fruit), and patients had the opportunity to undertake about an
hour of physical exercise every day.
Clinical assessment.

We obtained a complete medical history and physical examination from all participants, and participants with serious medical abnormalities were excluded. All schizophrenia patients were
inpatients. All participants were Han Chinese recruited at the same period from the Beijing area. Both the schizophrenia patients and the healthy controls revealed a similar socioeconomic status and dietary patterns. Healthy
controls (male/female = 80/80) were recruited from our local community. Current mental status and personal
or family history of mental illness was assessed using unstructured interviews. None of the healthy controls presented a personal or family history of psychiatric disorders. Neither the patients with schizophrenia nor the
healthy controls had a history of drug abuse or dependence.
Clinical assessments of patients were carried out by two psychiatrists who had more than five years of clinical
practice experience and who were blind to the clinical status and treatment conditions assessed the participants’
psychopathology using the positive and negative syndrome scale (PANSS)56. To ensure consistent and reliable
ratings, the two psychiatrists simultaneously attended a training session for standardizing their use of PANSS
prior to the start of the study. Thereafter, they maintained an intra-class correlation coefficient of greater than 0.8
on the PANSS at repeated assessments during the course of this study.

Cognitive assessment. All subjects were given cognitive function assessment using the MCCB18,57. A previous study by Zhou et al. at Beijing Huilong Guang Hospital showed that MCCB was valuable and reliable in
assessing cognitive function in Chinese Han schizophrenia patients and health controls19. The MCCB is comprised of 10 standardized measures that are used to calculate cognitive functions in 7 domains and a global
composite score. The MCCB battery consists of Trail Making Test Part A; Brief Assessment of Cognition in
Schizophrenia: Symbol coding; Hopkins Verbal Learning Test (HVLT); Wechsler Memory Scale Spatial span;
Digital Sequence Test; Neuropsychological Assessment Battery (NAB): Mazes; Brief Visuospatial Memory Test
(BVMT); Category Fluency; Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT): Managing Emotions;
and the Continuous Performance Test: Identical Pairs. The seven MCCB domains were: processing speed, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving and social
cognition58.
Statistical Analysis.

Group comparisons on the demographic and clinical variables used Chi squared or
Fisher exact tests for the categorical variables and Student t-tests or analysis of variance (ANOVA) for the continuous variables. For the MCCB comparisons, we included age and education as covariates in the multivariate
analyses of covariance (MANCOVA). We tested the main effect of diagnose (schizophrenia patients vs healthy
controls), gender (male vs female) and diagnosis x gender. Effect sizes were also calculated for the two-way
comparisons and represented the mean difference, in standard deviation units, between the groups of interest.
MANCOVA was used to further analyse these differences in cognitive functions. Bonferroni corrections were
applied to each test to adjust for multiple testing. To analysis the amount of variance in cognitive functioning
explained by the psychopathological variables, first-order multiple linear models were estimated by using the
least-squares estimator, while controlling for several potential confounders including age, gender, education,
duration of illness and PANSS (positive, negative, general pathological symptoms and the total score). To select a
subset of variables which were associated with the response, stepwise selection was used, where inclusion factors
for variable selection were set at a p-value < 0.05.
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